Study in human cells shows it counteracts Ebola’s defenses
Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly, highly contagious infection. In meticulous experiments in human cells, led by Boston Children’s Hospital, the drug significantly amplified immune responses to Ebola and inhibited Ebola replication.
The study, published in the Cell Press journal iScience, also showed how the drug works: It enhances the immune system’s ability to detect Ebola, normally impeded by the virus.
Nitazoxanide, or NTZ, is currently used to treat gastrointestinal infections caused by parasites such as Giardia and Cryptosporidium. It has been shown to be safe and even comes in a formulation for children. Study leader Anne Goldfeld, MD, of the Program in Cellular and Molecular Medicine at Boston Children’s, hopes that, with further testing and validation, it could be part of the solution for Ebola.
“Currently, there is no easily deployable therapy for Ebola virus,” she says. “There are some very promising vaccines, but there is no oral, inexpensive medication available.”
The Ebola virus caused more than 10,000 deaths in the 2014-2016 West African epidemic and more than 1,800 lives (as of August 6th) in the current outbreak in the Democratic Republic of the Congo. The virus is very good at evading human immune defenses. Though very small, it has two genes devoted to blocking immune responses.
Goldfeld and collaborators Chad Mire, PhD and Thomas Geisbert, PhD at the University of Texas Medical Branch, Galveston, showed in Biosafety Level 4 laboratory experiments that NTZ inhibits the Ebola virus (isolated from an earlier outbreak). Additional experiments performed in collaboration with Sun Hur, PhD of Boston Children’s showed that NTZ works by broadly amplifying the interferon pathway and cellular viral sensors, including two known as RIG-I and PKR. By deleting RIG-I and PKR in human cells through CRISPR editing, Goldfeld and University of Texas colleagues showed that NTZ works through these molecules to inhibit Ebola virus.
“Ebola masks RIG-I and PKR, so that cells don’t perceive that Ebola is inside,” explains Goldfeld. “This lets Ebola get a foothold in the cell and race ahead of the immune response. What we’ve been able to do is enhance the host viral detection response with NTZ. It’s a new path in treating Ebola.”
Goldfeld hopes to move into animal studies soon, especially given that NTZ has already been used in millions of people with minimal side effects. If effective, it could thus be easily repurposed for Ebola treatment or prevention.
The Latest on: Ebola
[google_news title=”” keyword=”Ebola” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Ebola
- Ebola Outbreak in West Africa, 2013-2014on February 29, 2024 at 4:00 pm
The Ebola virus disease outbreak now ravaging parts of West Africa is the largest on record. In fact, West Africa has seen more cases of the disease in 2014 than have been seen in all other ...
- Ebola's exponential growthon February 29, 2024 at 4:00 pm
The U.S. government’s Centers for Disease Control warned recently that we could have 1.4 million cases of Ebola by January. By Gwynne Dyer - Here are two good things about the Ebola virus. It is ...
- The Western Lowland Gorilla Is Susceptible to Ebolaon February 29, 2024 at 8:50 am
The western lowland gorilla (Gorilla gorilla gorilla) is fortunate enough to boast the highest population numbers of all gorilla subspecies, but they are still considered endangered. They can be found ...
- From Ebola to Dengue: Top 10 most dangerous viruses in the worldon February 29, 2024 at 3:11 am
The Marburg virus is a hemorrhagic fever virus. As with Ebola, the Marburg virus causes convulsions and bleeding of mucous membranes, skin and organs. It has a fatality rate of 90 percent. The Marburg ...
- Uganda receives 25,000 doses of Ebola vaccineson February 28, 2024 at 10:01 pm
Lt Col Dr Henry Kyobe, the Ebola incident commander at the ministry received a consignment of 25,060 doses of J & J Ebola vaccines to be used in preventive vaccination against Ebola in 20 target ...
- Ervebo Vaccine Saves Lives Even After Exposure to Ebolaon February 26, 2024 at 4:00 pm
The vaccine rVSVΔG-ZEBOV-GP (Ervebo) not only reduces the risk for Ebola infection but also halves mortality rates. This is the result of a study published in The Lancet Infectious Disease. Rebecca ...
- New Ebola and Marburg Guideline Addresses 'Inappropriate Practices'on February 26, 2024 at 8:17 am
The World Health Organization's (WHO) updated infection prevention and control (IPC) guideline for Ebola and Marburg disease aims to address "inappropriate practices" in the management of these ...
- Ebola vaccine cuts death rates in half — even if it's given after infectionon February 15, 2024 at 1:43 pm
Ebola is one of the most feared infectious diseases, with more than half of those infected dying. A vaccine has now been shown to cut that mortality rate in half.
- Ebola vaccine cuts death rates in half — even if it's given after infectionon February 15, 2024 at 9:43 am
There's welcome news in the battle against the Ebola virus, an infectious disease that for years had almost no treatments or remedies. Outbreaks of the deadly Ebola virus flare up in parts of ...
- Ebola vaccine cuts death rates in half — even if it’s given after infectionon February 15, 2024 at 2:18 am
JOHN WESSELS / John Wessels/AFP via Getty Images There's welcome news in the battle against the Ebola virus, an infectious disease that for years had almost no treatments or remedies. Outbreaks of ...
via Bing News